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by the many pharmacopoeia and formularies that appear in 
Switzerland and elsewhere.
In the early 19th century, when alkaloids appeared, the daily 
work of the pharmacist was altered by these new molecular 
substances. Most of the active ingredients were indeed isolat-
ed by pharmacists for the first time. Since 1850, new medicines 
arrived, especially the first products of organic chemistry 
which are initially antipyretic analgesics and sleeping pills. 
This phenomenon led to many changes: new formulations 
such as capsules, tablets and injectables, a more pharma-
cological vision of medicine and the take-off of pharmaceu-
tical industry. The latter grew rapidly, often from community 
pharmacists’ laboratories. Gradually, and especially during 
the 20th century, the proprietary medicine took over magistral 
formula, in particular as a result of major changes in thera-
peutic approaches and dosage forms.  Antibiotics, psychiatric 
medicines, hormonal products and many other medicines, 
developed since the early 20th century, were thus sold as 
proprietary drugs.
The pharmacist, who was still mostly developing tradi-
tional dosage forms such as pills and decoctions from whole 
extracts in 1900, lost his predominance in the manufacture 
of medicines. The advent of industrial society has therefore 
radically transformed the work of the pharmacist as well as 
his social image.
The new information technologies 4,5
Industrial society now seems to give way to a so-called 
information or knowledge society. What about then of the 
new professional world in which the pharmacist will evolve? 
Health systems are undergoing strong demographic, societal, 
economic and qualitative pressures. The medication  circuit 
represents therefore a major financial and security issue. 
Medicines professionals have throughout 
history regularly witnessed their activities 
changing and evolving. The pharmacy 
 profession is currently facing new 
 challenges in a changing world. In 2011 the 
Swiss Young Pharmacists Group (swissYPG) 
organized an educational and reflective 
symposium on this theme on the occasion  
of the first Swiss congress of pharmacists in 
Interlaken1. This article provides a compre-
hensive summary of the content of this 
symposium.4
The manufacture of medicines: from apothecary to 
industry 2, 3
Driven by the three pillars of traditional pharmacy, which are 
manufacturing, storage and administration of medicines, the 
pharmacist appeared in Europe in the 12th century under the 
impulse of change within Arab sciences. Galenics was then 
driving expansion of the profession. The apothecary manu-
factured many preparations, such as electuaries, pills and 
troches within the practice of polypharmacy. The pharmacist 
of the Middle Ages, and then of the Renaissance, found a legal 
and institutional basis supported by multiple regulations. 
Both the access to the profession and the education of the 
future apothecary were codified and emphasized two aspects: 
the book knowledge and the practical knowledge, reflecting 
the role of pharmacists in the manufacturing of medicines. 
Despite several paradigm shifts that affect treatment, such 
as spagyric medication of Paracelsus or new drugs from the 
Americas, the central place of the apothecary in manufactur-
ing continued until the 19th century. It is also established 
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In this context, the roles of health professionals are clearly 
destined to evolve. In parallel, patients are  increasingly 
 interconnected and want to have a voice. The future seems to 
be in the regional, national and international networks and 
expectations are high towards computer tools to improve 
medicine in the 21st century. These tools tend thus to become 
the nervous system of public health. We must be able to com-
municate, understand, decide, manage and develop our health 
systems in a world where information is becoming a real 
strategic issue, more and more every day.
In hospitals, for instance, computerization can reduce 
 complications, mortality rates and costs. However, poor adop-
tion or use of computer tools can be dramatic  (e-iatrogeny).  
A prerequisite for optimal benefit is the design of programs 
that are simple and ergonomic, connected and mobile, 
context-aware (localization, activity, vital signs, emotional 
status) and relying on a robust infrastructure (security, etc.). 
For outpatients, integrated, personalized and local IT services 
could also allow a better care of patients at home (e.g. Ambient 
Assisted Living program; AAL), given the aging population and 
growing incidence of chronic diseases.  Telemedicine is also 
gaining importance and seems to improve patient comfort 
and care within regions with few health care providers. Finally, 
health information networks projects (e.g. e-toile in Geneva) 
could improve the quality and efficiency of care by efficiently 
sharing information among all health care providers while 
actually putting the patient at the center of the process.
Thus, like their medicine and nursing confreres, community 
pharmacists (including those involved in home care), as well 
as hospital or industry pharmacists, are expected to integrate 
these new paradigms and tools in their practice, while remain-
ing able to judge their actual usefulness for optimal manage-
ment of the patient.
Pharmaceutical industry’s development strategies 6,7
Forced by the high attrition rate of late stage medicine 
 candidates, and increasingly empty pipelines, several 
strategies are being followed by pharmaceutical industries 
to increase the number of candidates. Among them is the 
 establishment of high throughput screening methods to 
search large libraries of chemical structures and to identify 
potential medicinal candidates. However, high expectations 
of this approach have not entirely been met and the  human 
 experience may prove to be as efficient (e.g. thanks to the 
Lipinski «Rules of 5» to evaluate drug likeness). Another 
approach is the development of biologicals (proteins and 
 antibodies). They have been the driver of innovation for the 
last few years, made possible by the advancement of stud-
ies on their basis of action, stemming from proteomics and 
genomics. Another buzz-word in current medicines develop-
ment is “Individualized Medicine”, which takes into account 
the impact of differences between patients on drugs’ efficacy 
(target expression, pharmacokinetics, pharmacogenetics, 
etc.). Trastuzumab is an example. More and more, therapeutics 
will be accompanied by so-called “companion diagnostics”. 
Last but not least, portfolio management, i.e. the search for 
additional indications for the same medicine (by various 
 approaches such as reverse genetics) or acquisition of biotech 
companies to obtain access to new medicines candidates are 
other opportunities for “Big Pharma”.
However, such novelties must be knowledge-based, which 
 demands a close interaction between academia and  industry. 
This cooperation is yet not easy to manage  (different assump-
tions, conflict of interests, etc.). Academia is interested in 
creating and diffusing knowledge, although it is also slowly 
moving to market activities (papers publication to acquire 
funding, patenting, etc.). Academic scientists are yet often 
being focused too much on the fundamental side of drug 
discovery and development, neglecting the translational 
approach in which their findings should be translated into a 
real-world product. To the contrary, drug development in the 
corporate world is designed to create revenue for the com-
pany. In an industrial environment, scientific creativity is often 
suppressed. Industrial organizations are aware of these limita-
tions and strive to either implement “biotech-like” structures 
in drug discovery and early development, or seek interaction 
with academic institutions (called a “collaboration bubble”). 
In addition, multilateral “open innovation” models do exist, 
in which knowledge is shared between several partners from 
academia and industry, often using “Web 2.0” tools (e.g. “Open 
Source Drug Discovery” network, for novel anti-tuberculosis 
drugs). For community and clinical pharmacy, such new de-
velopments should have a significant impact (e.g. diagnostic/ 
monitoring kits, etc.).
Fig. 1. Round table
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Round table and discussion
The Swiss YPG symposium tracked past and present evolu-
tions of the pharmacist, by giving us the opportunity to think 
about the future of this profession. A historical perspective 
has first allowed following the impressive developments 
and changes in the pharmacy profession throughout the 
last centuries. In the new environment of information 
techno logies and of a health system confronted with major 
demographic changes, the drug is now considered also in 
terms of costs and risks. Therefore, the pharmacist can, and 
has to, significantly contribute to teams and networks of 
care. The situation in the pharmaceutical industry was finally 
presented from the scientist’s viewpoint with experience in 
both industry and academics. Pharmaceutical companies are 
seeking new collaborations with universities to bring more 
medicines into the pipeline.
The roundtable (Fig. 1) also allowed addressing the issue of 
education of pharmacists. Given the employment market, 
the question arises whether it meets the changes observed 
(Fig. 2). Are young pharmacists able to make the right career 
choice at the end of their studies? Are graduates “fit for use”?
In addition to preparing to federal exam, the fifth year of 
study is also the crucial period of career orientation. The 
studies’ reform had an “assessment area” much larger and 
wider in time that is possible in Switzerland today. One 
should consider the duration of studies of natural and medi-
cal sciences in the context of international competition for 
work. This raises the question whether the strength and 
excellence of Swiss dual education system (both academic 
scientific studies and university of applied sciences, profes-
sional practice-oriented) can be applied to the pharmacy. 
At any rate, social and practical skills, poorly transmitted 
during university studies, should also be provided to a 
generation that already generates new social interaction 
via the Internet. These capabilities are often crucial for the 
job’s success and satisfaction. However, unlike in the past, 
individual career orientation will often be modified, notably 
by the influence of the balancing between work and family 
activities. All this highlights the importance of lifelong learn-
ing, i.e. continuing education; one speaker also talked about 
the need for a professional realignment every ten years.
Comments from young pharmacists, faced with the crucial 
period between graduation and first job, are very important. 
They provide reflection on the effective adaptation of educa-
tion and training in pharmacy, both in term of content and of 
their arrangement, as well as in their durability against the 
evolving needs of the profession8. This symposium showed 
in this regard that an important responsibility lies on the 
swissYPG because of the reflection platform it provides. In 
 concert with other health professionals and peers, it can 
help to build better pharmaceutical roads and to define the 
future of pharmacy, ultimately for the benefit of the patient.
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Fig. 2. Undergraduate and continuing education: fit for use? (courtesy of pharmaSuisse)
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ACCOMPANYING COMMENTARY ON FUTURE PERSPECTIVES OF PHARMACY
Florian Sarkar, swissYPG
The Swiss YPG symposium highlighted a crucial fact that 
change in the pharmaceutical sciences is a continuum that 
presently appears to accelerate. Professional evolutions are 
however often a matter of great concern for pharmacists.
Change is a natural process that occurs in virtually every 
part of life. We should therefore not fear change for the sake 
of loss and insecurity, but take it as a chance for improve-
ment and new opportunities. Pharmacists should take 
advantage of the opening gaps in healthcare systems and 
demonstrate the value of their profession not just as medi-
cines dispensers, but as medicines experts providing high 
quality services.
In order to promote a role in health care that is both ben-
eficial to society and gratifying for ourselves, we have to 
extend the duty of executing a physician’s therapy instruc-
tions. Instead we have to learn to take personal responsibil-
ity for therapeutic patient interventions. Instead of focusing 
on the legal limits defining our profession, we should rely 
more on our wide knowledge and develop practice in a way 
that matches both our true abilities and societal needs. We 
have to go ahead of political process and prove the value of 
our work to obtain a juridical and political position that ac-
tually corresponds to what we can bring to the population.
In parallel, we must also closely keep contact with other 
health care professionals. The more we cooperate and 
participate in joint therapeutic projects, the more will other 
professions know and appreciate our competence. 
By positively facing the challenges of future health  policy, 
we can provide useful and safe health care service to 
 patients together.
At present, another challenge is to cope with the rapidly 
growing amount of medical and scientific knowledge. The 
pharmacist’s education has to adopt the newest trends of 
information technology. In our future, we will indeed regu-
larly use connected computers, tablets and smart phones as 
quick and flexible tools of storing, transferring and sharing 
information. There is also a strong need that complete 
clinical patient data are quickly available to all involved 
care providers. Yet the establishment of a broadly accepted 
E-Health strategy will face a long political process in every 
country. Pharmacists can take influence here as health care 
experts with large experience in handling patient data for 
medicines management.
The future of the pharmacy profession depends on the 
personal attitude of every single professional. The will to 
keep up with current pharmaceutical knowledge and tech-
nologies has to be our mindset. If we believe in our abilities, 
we can lead our profession towards a bright future where 
pharmacists participate in creating a healthier world.
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